News Image

Why NASDAQ:AMGN is a Top Pick for Dividend Investors.

By Mill Chart

Last update: Jan 12, 2024

Consider AMGEN INC (NASDAQ:AMGN) as a top pick for dividend investors, identified by our stock screening tool. NASDAQ:AMGN shines in terms of profitability, solvency, and liquidity, all while paying a decent dividend. Let's dive deeper into the analysis.

Analyzing Dividend Metrics

ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NASDAQ:AMGN was assigned a score of 7 for dividend:

  • Compared to an average industry Dividend Yield of 13.76, AMGN pays a better dividend. On top of this AMGN pays more dividend than 98.48% of the companies listed in the same industry.
  • AMGN's Dividend Yield is a higher than the S&P500 average which is at 2.45.
  • The dividend of AMGN is nicely growing with an annual growth rate of 10.76%!
  • AMGN has paid a dividend for at least 10 years, which is a reliable track record.
  • AMGN has not decreased their dividend for at least 10 years, which is a reliable track record.

Unpacking NASDAQ:AMGN's Health Rating

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:AMGN has earned a 5 out of 10:

  • AMGN has a Altman-Z score of 1.83. This is in the better half of the industry: AMGN outperforms 64.81% of its industry peers.
  • The Debt to FCF ratio of AMGN (6.45) is better than 94.59% of its industry peers.
  • AMGN has a Current Ratio of 2.86. This indicates that AMGN is financially healthy and has no problem in meeting its short term obligations.
  • AMGN has a Quick Ratio of 2.56. This indicates that AMGN is financially healthy and has no problem in meeting its short term obligations.

How do we evaluate the Profitability for NASDAQ:AMGN?

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:AMGN, the assigned 8 is a significant indicator of profitability:

  • The Return On Assets of AMGN (8.36%) is better than 97.12% of its industry peers.
  • Looking at the Return On Equity, with a value of 98.82%, AMGN belongs to the top of the industry, outperforming 99.66% of the companies in the same industry.
  • AMGN's Return On Invested Capital of 10.97% is amongst the best of the industry. AMGN outperforms 96.62% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for AMGN is above the industry average of 13.22%.
  • The 3 year average ROIC (16.82%) for AMGN is well above the current ROIC(10.97%). The reason for the recent decline needs to be investigated.
  • Looking at the Profit Margin, with a value of 28.20%, AMGN belongs to the top of the industry, outperforming 98.14% of the companies in the same industry.
  • AMGN's Profit Margin has improved in the last couple of years.
  • AMGN's Operating Margin of 33.95% is amongst the best of the industry. AMGN outperforms 98.14% of its industry peers.
  • AMGN has a better Gross Margin (73.74%) than 83.76% of its industry peers.

Our Best Dividend screener lists more Best Dividend stocks and is updated daily.

Our latest full fundamental report of AMGN contains the most current fundamental analsysis.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

AMGEN INC

NASDAQ:AMGN (4/26/2024, 7:00:00 PM)

After market: 270.3 +0.32 (+0.12%)

269.98

+0.6 (+0.22%)

AMGN News

News Image2 days ago - AmgenAMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency...

News Image5 days ago - The Motley FoolBetter Buy: Pfizer vs. Viking Therapeutics

These two pharma stocks have followed distinct paths of late. Which is the better investment?

News Image5 days ago - The Motley Fool1 No-Brainer Vanguard Fund to Buy Right Now

This Vanguard growth fund is home to some of the world's most innovative companies.

News Image9 days ago - InvestorPlaceThe Dividend Goldmine: 3 Shining Stocks With Growing Payouts

Explore opportunities in the cable, restaurant and biotechnology sectors, revealing how dividend growth stocks are maximizing returns.

News Image10 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Amgen
News Image11 days ago - Market News VideoNoteworthy Wednesday Option Activity: UPS, AMGN, BMEA
News Image11 days ago - InvestorPlaceSell These 3 Blue-Chip Stocks Before the Next Earnings Stumble

Though stocks that make the Dow 30 are often seen as solid investments, investors should consider these three blue chip stocks to sell.

News Image11 days ago - InvestorPlaceComing FDA Approvals Could Send These 3 Drug Stocks Soaring

When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.

News Image11 days ago - The Motley FoolCan This High-Yield Dividend Stock Keep Beating the S&P 500?

Amgen's shares have come under pressure this year, making it a compelling bargain buy.

News Image11 days ago - The Motley FoolGot $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever

Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.

News Image12 days ago - AmgenAMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic...

News Image12 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy Now: Q2 Edition

Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.

AMGN Links
Follow us for more